Atara Biotherapeutics Holds Special Stockholder Meeting
Ticker: ATRA · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
Related Tickers: ATRA
TL;DR
ATRA held a shareholder vote on 6/10/25, expect news soon.
AI Summary
On June 10, 2025, Atara Biotherapeutics, Inc. filed an 8-K report indicating that it held a special meeting of stockholders on June 10, 2025. The primary purpose of this meeting was for security holders to vote on certain matters.
Why It Matters
This filing signals a corporate event where shareholder decisions are being made, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — The filing is a routine procedural report about a shareholder meeting and does not contain new financial or operational information that would immediately impact risk.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
FAQ
What was the specific date of the special meeting of stockholders?
The special meeting of stockholders was held on June 10, 2025.
What is the company's full legal name as specified in its charter?
The company's full legal name is Atara Biotherapeutics, Inc.
In which state was Atara Biotherapeutics, Inc. incorporated?
Atara Biotherapeutics, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The principal executive office is located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.
What is the purpose of this Form 8-K filing?
This Form 8-K is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting the submission of matters to a vote of security holders.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).